1. Academic Validation
  2. KDM3A Ablation Activates Endogenous Retrovirus Expression to Stimulate Antitumor Immunity in Gastric Cancer

KDM3A Ablation Activates Endogenous Retrovirus Expression to Stimulate Antitumor Immunity in Gastric Cancer

  • Adv Sci (Weinh). 2024 Jul 19:e2309983. doi: 10.1002/advs.202309983.
Jiabin Zheng 1 Huolun Feng 1 2 Jiatong Lin 1 2 Jianlong Zhou 1 Zhihui Xi 2 Yucheng Zhang 1 Fa Ling 1 Yongfeng Liu 1 Junjiang Wang 1 Tieying Hou 3 4 Fan Xing 5 Yong Li 1 2
Affiliations

Affiliations

  • 1 Department of Gastrointestinal Surgery, Department of General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, China.
  • 2 School of Medicine, South China University of Technology, Guangzhou, Guangdong, 510006, China.
  • 3 Medical Experimental Center, Shenzhen Nanshan People's Hospital, Shenzhen, Guangdong, 518052, China.
  • 4 Shenzhen University Medical School, Shenzhen, Guangdong, 518073, China.
  • 5 Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, 510080, China.
Abstract

The success of immunotherapy for Cancer treatment is limited by the presence of an immunosuppressive tumor microenvironment (TME); Therefore, identifying novel targets to that can reverse this immunosuppressive TME and enhance immunotherapy efficacy is essential. In this study, enrichment analysis based on publicly available single-cell and bulk RNA Sequencing data from gastric Cancer patients are conducted, and found that tumor-intrinsic interferon (IFN) plays a central role in TME regulation. The results shows that KDM3A over-expression suppresses the tumor-intrinsic IFN response and inhibits KDM3A, either genomically or pharmacologically, which effectively promotes IFN responses by activating endogenous retroviruses (ERVs). KDM3A ablation reconfigures the dsRNA-MAVS-IFN axis by modulating H3K4me2, enhancing the infiltration and function of CD8 T cells, and simultaneously reducing the presence of regulatory T cells, resulting in a reshaped TME in vivo. In addition, combining anti-PD1 therapy with KDM3A inhibition effectively inhibited tumor growth. In conclusions, this study highlights KDM3A as a potential target for TME remodeling and the enhancement of antitumor immunity in gastric Cancer through the regulation of the ERV-MAVS-IFN axis.

Keywords

ERV; KDM3A; gastric cancer; immunotherapy.

Figures
Products